FDA Approval Summary: Dabrafenib in combination with trametinib for BRAF V600E mutation-positive low-grade glioma. Barbato MI, Nashed J, Bradford D, Ren Y, et al. Clin Cancer Res 2023 Aug 23:CCR-23-1503. doi: 10.1158/1078-0432.CCR-23-1503.

Read + Share

Amedeo Smart

Independent Medical Education

Barbato MI, Nashed J, Bradford D, Ren Y, et al. FDA Approval Summary: Dabrafenib in combination with trametinib for BRAF V600E mutation-positive low-grade glioma. Clin Cancer Res 2023 Aug 23:CCR-23-1503. doi: 10.1158/1078-0432.CCR-23-1503.
PMID: 37610803